"With CP-012, we are working to change when levodopa works, not what it is, so that people with Parkinson’s can start their day without waiting for their medication to take effect.”
Anne Birk Østerskov,
Chief Medical Officer
Latest news
-
Lundbeck and Contera Pharma
Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical...
-
CP-012: Positive topline results in Phase 1b trial
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease Hørsholm, September 17, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline results in a Phase 1b pharmacoscintigraphic study evaluating CP-012....
-
Last patient dosed in Phase 1b trial of CP-012
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the last patient has been dosed in its Phase 1b...